hVIVO (LON:HVO) Stock Price Up 8% – Still a Buy?

hVIVO plc (LON:HVO) shares traded up 8% on Wednesday . The company traded as high as GBX 6.50 and last traded at GBX 6.48. 1,554,628 shares changed hands during trading, a decline of 38% from the average daily volume of 2,515,174 shares. The stock had previously closed at GBX 6.

hVIVO Stock Performance

The firm has a market cap of £44.59 million, a price-to-earnings ratio of -7.45 and a beta of 1.69. The stock’s 50 day moving average is GBX 6.71 and its 200 day moving average is GBX 7.32. The company has a current ratio of 1.21, a quick ratio of 1.16 and a debt-to-equity ratio of 43.38.

hVIVO (LON:HVO) last released its earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. Analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.